Skip to main content
. 2018 Nov 12;8(21):5890–5902. doi: 10.7150/thno.27667

Figure 1.

Figure 1

BPI-9016M suppresses tumor growth in lung adenocarcinoma. (A) Two primary tumor cells and six cell lines of lung adenocarcinoma were treated with serially diluted BPI-9016M for 48 h and IC50 was calculated as shown in the bar graph. (B) QPCR (top panel) and Western blot (bottom panel) analyses show c-Met expression in lung adenocarcinoma cell lines including H1299, A549, H1975, PC-9, H1650 and HCC827. (C) Tumor growth inhibition in PDX1, PDX2, PDX3 and PDX4 models following BPI-9016M treatment. (D) Tumor volume in the PDX1, PDX2, PDX3 and PDX4 models with BPI-9016M or vehicle treatment. * p<0.05, ** p<0.01, *** p<0.001 at indicated time point. (E) Representative images (×200 magnification) of c-Met by immunohistochemical staining of the BPI-9016M-treated PDX1 and PDX4 tissues. (F) H-score to evaluate c-Met expression and tumor growth inhibition (TGI) in the four PDX models after administration of BPI-9016M. (G) Representative images (×200 magnification) of Ki67 staining of the PDX1 tumors with vehicle or BPI-9016M treatment.